Steven L. Hoerter insider trades

Open-market stock purchases and sales by Steven L. Hoerter, President and CEO at MBX Biosciences, Inc, from SEC Form 4 filings since Mar 1, 2012.

Track record: 100% of 1 scored buy are up 5% or more since purchase, averaging +281%.

Recent trades

DateStockTradeValue
Aug 3, 2026MBX MBX Biosciences, IncBought (not open market)—
Aug 3, 2026MBX MBX Biosciences, IncBought (not open market)—
Jun 24, 2026CCCC C4 Therapeutics, IncBought (not open market)—
Jun 4, 2026MBX MBX Biosciences, IncBought (not open market)—
May 1, 2026MBX MBX Biosciences, IncBought (not open market)—
May 1, 2026MBX MBX Biosciences, IncBought (not open market)—
Jan 2, 2026ORIC Oric Pharmaceuticals, IncBought (not open market)—
Nov 22, 2025MBX MBX Biosciences, IncBought (not open market)—
Nov 22, 2025MBX MBX Biosciences, IncBought (not open market)—
Nov 6, 2025MBX MBX Biosciences, IncBought (not open market)—
Nov 6, 2025MBX MBX Biosciences, IncBought (not open market)—

Companies traded

  • MBX MBX Biosciences, Inc: 1 buy, last Aug 3, 2026
  • CCCC C4 Therapeutics, Inc: other filings, last Jun 24, 2026
  • ORIC Oric Pharmaceuticals, Inc: other filings, last Jan 2, 2026
  • DCPH Deciphera Pharmaceuticals, Inc: 4 sales, last Feb 15, 2024
  • CNST Constellation Pharmaceuticals Inc: other filings, last Jul 15, 2021
  • AGIO Agios Pharmaceuticals Inc: 10 sales, last Mar 4, 2019
  • RXDX Ignyta, Inc: other filings, last Feb 8, 2018
  • CLVS Clovis Oncology, Inc: 5 sales, last Mar 5, 2015

Get free alerts when Steven L. Hoerter files a new trade →